Navigation Links
Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
Date:10/26/2008

ns; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Contacts:

Pam Van Houten

Mobile: (908) 295-7367


'/>"/>
SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Scientists at,deCODE genetics, Inc. (Nasdaq: DCGN ) ... version of a common single-letter variant in the ... impact on susceptibility to type 2,diabetes (T2D). The ... large, but unusual:,if an individual inherits it from ... more than 30% compared to those who inherit ...
(Date:12/16/2009)... Cohera Medical Inc. today announced the treatment of ... lead surgical adhesive product, TissuGlu®. Initiation of the ... progression of the lead product toward clinical practice. ... open-label, randomized study to investigate the safety of ... associated complications in abdominoplasty, or "tummy tuck," surgeries. ...
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
Breaking Medicine Technology:deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3CareCentrix Receives URAC Health Utilization Management Accreditation 213 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 113 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 2Red Cross Strives to Help Disasters Vulnerable Population 59839 1Red Cross Strives to Help Disasters Vulnerable Population 59839 2Red Cross Strives to Help Disasters Vulnerable Population 59839 3Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 1Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 2
... presented at ICAAC -, BRIDGEWATER, N.J., Sept. ... open-label Phase 3 study showed that 84 percent ... of,PREZISTA(TM) (darunavir) 800 mg (two 400 mg tablets) ... and tenofovir disoproxil,fumarate) reached an undetectable viral load ...
... 18 - A,multi-disciplinary group of researchers from the ... Maryland Biotechnology Institute (UMBI),has won a competitive, $2 ... way researchers develop and test pharmaceutical drugs., ... Distinguished,Professor and chair of the Fischell Department of ...
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a ... one of its portfolio companies, Acclarent, Inc., has ... by Ethicon, Inc., a Johnson & Johnson company, ... (net of estimated cash on hand at time ... designing, developing and commercializing devices that address conditions ...
(Date:12/16/2009)... never felt so good for "The Biggest Loser" Danny ... continuing to make smart choices everyday to help him ... choice that is an important part of living well. ... glass of milk has nine essential nutrients like protein ... pressure, and calcium and vitamin D for strong bones. ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... role in reducing inflammation in the lungs , , WEDNESDAY, ... plays a role in inflammation seems to protect the ... who smoke. , Researchers also found that adult smokers ... lower risk of developing chronic obstructive pulmonary disease (COPD), ... "The gene seems to be protective of the lungs ...
(Date:12/16/2009)... omega-3 essential fatty acids commonly found in fatty ... according to research published by the American Psychological ... information-processing problems found in people with schizophrenia; bipolar, ... other afflictions of the nervous system. , ... Neuroscience , provides more evidence that fish is ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:New study links DHA type of omega-3 to better nervous-system function 2
... association exists between depression severity and poor Glycaemic control ... of the diabetics were found having received mental health ... Columbia University's Mailman School of Public Health and College ... 200 Hispanics with diabetes. "We found a steady increase ...
... genetics, more importance is being given to the tendency of ... the same. // A recent study has now shown that ... on dialysis. ,What is even more alarming is ... that can be treated at early stages. Family members of ...
... survival rate of patients with testicular cancer has increased significantly ... now shown that fatherhood is a reachable possibility for many ... the most common form of cancer among men ages 20 ... side than on the left. The cause for the cancer ...
... Research has leaned in a big way towards eating up ... studies presented at the meeting extolled on the virtues of ... experts are now of the view that the best way ... you eat, in other words diet modification may actually add ...
... US and University of Tokyo, Japan have found a faster ... a bird flu outbreak involving mutant strain of virus occurs. ... the avian virus which may be very lethal and may ... University of Wisconsin-Madison, working with Japanese colleagues from the University ...
... an important signaling pathway in prostate cancer cells, thereby ... of Vitamin E // that limits the proliferation of ... study are the first to describe the role of ... TAP in prostate cancer. Expression levels of TAP are ...
Other Medicine News:Health News:Testicular Cancer Patients Have Improved Reproductive Outcomes After Treatment 2Health News:Faster way of producing Bird flu vaccine using Reverse Genetics 2
... Ophthalmoscope with superior aspherical optics. The separation ... of the aspherical optical system avoids corneal ... allows you to view the whole of ... with a small pupil. Conventional ophthalmoscopes often ...
... Heine Beta 200S is the ... a combination of patented aspherical ... a range of corrective lenses ... in single diopter steps. A ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
Medicine Products: